The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma

被引：0

作者：

Kekre, Natasha ^{[1
]}

Marquez-Malaver, Francisco J. ^{[2
]}

Caballero, Dolores ^{[3
]}

Pinana, J. I. ^{[4
]}

Esquirol, Albert ^{[5
]}

Soiffer, Robert J. ^{[6
]}

Cabrero, Monica ^{[7
]}

Terol, M. J. ^{[4
]}

Martino, Rodrigo ^{[8
]}

Antin, Joseph H. ^{[9
]}

Lopez Corral, L. ^{[7
]}

Solano, Carlos ^{[10
]}

Armand, Philippe ^{[1
]}

Perez-Simon, Jose A. ^{[11
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Seville, CSIC, Hosp Univ Virgen Rocio, Dept Hematol,Inst Biomed Sevilla IBIS, Seville, Spain

[3] Hosp Univ Salamanca, Salamanca, Spain

[4] Hosp Clin Univ, Dept Hematol Oncol, Valencia, Spain

[5] Hosp Santa Creu & Sant Pau, Jose Carreras Leukemia Res Inst, Clin Hematol Serv, Barcelona, Spain

[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[7] Univ Salamanca, Inst Biosanitario Salamanca IBSAL, Univ Hosp, Hematol Serv, E-37008 Salamanca, Spain

[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[9] Childrens Hosp, Dana Farber Canc Inst, Massachusetts Gen, Boston, MA 02115 USA

[10] Hosp Clin Univ La Fe, Dept Hematol, Valencia, Spain

[11] Hosp Univ Virgen del Rocio, Dept Hematol, Seville, Spain

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[21] Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen
Osamu Imataki
Hiroaki Ohnishi
Yumiko Ohbayashi
Akira Kitanaka
Yoshitsugu Kubota
Toshihiko Ishida
Terukazu Tanaka
International Journal of Clinical Oncology, 2009, 14 : 197 - 201
[22] Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases
Nishimura, Akira
Aoki, Yuki
Ishiwata, Yasuyoshi
Ichimura, Takuya
Ueyama, Junichi
Kawahara, Yuta
Tomoda, Takahiro
Inoue, Maiko
Matsumoto, Kazuaki
Inoue, Kento
Hiroki, Haruka
Ono, Shintaro
Yamashita, Motoi
Okano, Tsubasa
Tanaka-Kubota, Mari
Ashiarai, Miho
Miyamoto, Satoshi
Miyawaki, Reiji
Yamagishi, Chika
Tezuka, Mari
Okawa, Teppei
Hoshino, Akihiro
Endo, Akifumi
Yasuhara, Masato
Kamiya, Takahiro
Mitsuiki, Noriko
Ono, Toshiaki
Isoda, Takeshi
Yanagimachi, Masakatsu
Tomizawa, Daisuke
Nagasawa, Masayuki
Mizutani, Shuki
Kajiwara, Michiko
Takagi, Masatoshi
Kanegane, Hirokazu
Imai, Kohsuke
Morio, Tomohiro
JOURNAL OF CLINICAL IMMUNOLOGY, 2021, 41 (05) : 944 - 957
[23] Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan
Sweiss, Karen
Calip, Gregory Sampang
Holden, Jaime
Lewkowski, Paulina
Mialik, Iryna
Johnson, Jeremy
Galvin, John P.
Rondelli, Damiano
Patel, Pritesh
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021, 27 (03) : 579 - 587
[24] Fludarabine and melphalan conditioning with tacrolimus as GvHD prophylaxis is effective reduced-intensity combination regimen for allogeneic stem cell transplant recipients compared to conventional regimen
Imataki, O.
Ohnishi, H.
Kitanaka, A.
Kubota, Y.
Tanaka, T.
Ishida, T.
BONE MARROW TRANSPLANTATION, 2007, 39 : S93 - S93
[25] Fludarabine and melphalan conditioning with tacrolimus as GVHD prophylaxis for allogeneic stem cell transplant recipients is an effective reduced-intensity combination regimen compared to the conventional regimen
Imataki, Osamu
Ohnishi, Hiroaki
Ohbayashi, Yumiko
Kitanaka, Akira
Kubota, Yoshitsugu
Ishida, Toshihiko
Tanaka, Terukazu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (03) : 197 - 201
[26] Hematopoietic Cell Transplantation with Reduced Intensity Conditioning Using Fludarabine/Busulfan or Fludarabine/Melphalan for Primary Immunodeficiency Diseases
Akira Nishimura
Yuki Aoki
Yasuyoshi Ishiwata
Takuya Ichimura
Junichi Ueyama
Yuta Kawahara
Takahiro Tomoda
Maiko Inoue
Kazuaki Matsumoto
Kento Inoue
Haruka Hiroki
Shintaro Ono
Motoi Yamashita
Tsubasa Okano
Mari Tanaka-Kubota
Miho Ashiarai
Satoshi Miyamoto
Reiji Miyawaki
Chika Yamagishi
Mari Tezuka
Teppei Okawa
Akihiro Hoshino
Akifumi Endo
Masato Yasuhara
Takahiro Kamiya
Noriko Mitsuiki
Toshiaki Ono
Takeshi Isoda
Masakatsu Yanagimachi
Daisuke Tomizawa
Masayuki Nagasawa
Shuki Mizutani
Michiko Kajiwara
Masatoshi Takagi
Hirokazu Kanegane
Kohsuke Imai
Tomohiro Morio
Journal of Clinical Immunology, 2021, 41 : 944 - 957
[27] IMMUNE RECONSTITUTION IN SCID PATIENTS AFTER ALEMTUZUMAB, FLUDARABINE, AND MELPHALAN REDUCED INTENSITY CONDITIONING ALLOGENETIC HSCT.
Abdalgani, Manar M.
Marsh, Rebecca
JOURNAL OF CLINICAL IMMUNOLOGY, 2016, 36 (03) : 253 - 253
[28] Long-term results of fludarabine/melphalan as reduced-intensity conditioning regimen in mantle cell lymphoma: age matters
Gayoso, J.
Martino, R.
Balsalobre, P.
Heras, I.
Pinana, J. L.
Serrano, D.
De la Serna, J.
Tomas, J. F.
Fernandez de Sevilla, A.
Sureda, A.
Diez-Martin, J. L.
Caballero, D.
BONE MARROW TRANSPLANTATION, 2009, 43 : S208 - S208
[29] Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: the GELTAMO experience
Gayoso, Jorge
Martino, Rodrigo
Balsalobre, Pascual
Heras, Inmaculada
Luis Pinana, Jose
Serrano, David
de la Serna, Javier
Francisco Tomas, Jose
Luis Diez-Martin, Jose
Caballero, Dolores
THERAPEUTIC ADVANCES IN HEMATOLOGY, 2011, 2 (01) : 5 - 10
[30] Patients with non-Hodgkin lymphoma receiving treosulfan and fludarabine as reduced-intensity conditioning
Schmitt, M.
Trenschel, R.
Sayer, H. G.
Schneider, C.
Glass, A.
Hilgendorf, I.
Treschl, A.
Junghanss, C.
Borchert, K.
Koenigsmann, M.
Casper, J.
Beelen, D. W.
Freund, M.
Kahl, C.
ONKOLOGIE, 2011, 34 : 299 - 300

← 1 2 3 4 5 →